Strategic Alliance: Shanghai Taimed Medical Visits AccuPulse Medical to Shape the Future of Electrophysiology

April 21,Zhang Dongdi, General Manager of Shanghai Taimei Medical, a wholly-owned subsidiary of Xinhua Medical, visited AccuPulse Medical Technology Co., Ltd.The two parties engaged in in-depth strategic exchanges on the co-construction of regional platforms, innovations in electrophysiological technology, and industry development trends, injecting new momentum into the production-research collaboration in the field of cardiac electrophysiology.

In recent years, China's electrophysiology market has been developing rapidly at an average annual growth rate of 25%, showing great market potential. However, imported brands still occupy over 85% of the market share, leaving broad space for domestically produced alternatives. With national policies supporting the localization of high-end medical devices and the expanding patient base suffering from arrhythmias such as atrial fibrillation and ventricular tachycardia, domestic electrophysiology companies are encountering an unprecedented golden window period.

Technological Breakthrough:Innovative technologies such as Pulse Field Ablation (PFA) and intelligent 3D mapping systems are accelerating the industry's advancement into precision and minimally invasive procedures.

Precision Treatment:Personalized ablation solutions and AI-assisted surgical planning have become clinical necessities, offering patients safer and more efficient treatment options.

Grassroots Penetration:High-Cost-Performance Products Made in China Facilitate Technology Penetration, Covering More Hospitals in Second- and Third-Tier Cities, Benefiting a Wider Patient Population.

AccuPulse Medical Technology Co., Ltd. was founded in November 2020. It is a company focused on platform-based technological innovation in the field of cardiac electrophysiology. With pulsed field ablation (PFA) and innovative three-dimensional mapping technology as its core, the company has developed more than 10 product pipelines covering the entire process of diagnosis and treatment for arrhythmias such as atrial fibrillation and premature ventricular contractions. In April 2023, AccuPulse's self-developed AccuPulse Cardiac Pulse Ablation System successfully completed all clinical study enrollments, placing it among the top tier of global pulsed field product clinical research. This marks that China-produced electrophysiological technology has reached an internationally leading level.

On April 29, 2025, the cardiac pulse ablation system independently developed by AccuPulse Medical Technology Co., Ltd. officially passed the approval of China's National Medical Products Administration (NMPA) and was launched in China! The approved AccuPulse cardiac pulse ablation system was verified by 17 electrophysiology experts from 8 research centers across China, achieving a 100% immediate success rate during procedures.

Shanghai TaiMei Medical Device Co., Ltd. was established in 2009 as a wholly-owned subsidiary of XinHua Medical. It focuses on comprehensive services for medical device logistics, distribution, and supply chain management. Based on a logistics network covering all of China, the company provides full-chain services such as channel management, market access, logistics distribution, and marketing support to internationally renowned medical device manufacturers and over a thousand tertiary hospitals in China. Since 2012, it has been continuously certified with ISO series quality certifications for 12 years.

Adhering to the cultural philosophy of "Dedication, Cooperation, Innovation, and Care," the company focuses on the orthopedics field while extending into three major sectors: dental, rehabilitation, and medical devices. This forms a "one-body-three-wing" strategic layout, with key coverage in high-value consumables and equipment areas such as joints, trauma, spine, sports medicine, dental implants, rehabilitation braces, insufflators, and neurointerventional products. Relying on a professional operating system, international quality control standards, and a multi-field collaborative development model, TaiMei Medical is committed to becoming an efficient and trustworthy industry benchmark enterprise. It aims to create value for upstream and downstream customers in the industrial chain while continuously driving innovation and upgrading experiences in medical device distribution services.

During this visit, Yin Jie, CEO of AccuPulse, presented the technical features of the PFA cardiac pulse ablation system and the three-dimensional mapping system to Zhang's team from TaiMei in detail. Through real-time three-dimensional heart modeling, the intelligent ablation path planning system was vividly demonstrated. When pulse energy achieved millimeter-level precise ablation on simulated myocardial tissue, the TaiMei team nodded frequently: "The feature of 'no eschar, no damage' perfectly solves the clinical pain points of traditional radiofrequency ablation." When local innovative forces resonate with professional operation platforms, China's cardiovascular intervention solutions are writing new world coordinates.

During this meeting, the two parties reached multiple consensuses on future cooperation:

1. Supply Chain Optimization:Relying on the nationwide logistics and distribution network of AccuPulse, improve the efficiency of product delivery to hospitals and the speed of logistics response to ensure timely fulfillment of clinical needs;

2. Market Co-expansion:Jointly carry out new consignment models, equipment rental and deployment activities to increase the market share of the AccuPulse brand.

3. Innovative R&D:Explore the deep integration of electrophysiology consumables with AI technology to develop smarter and more precise surgical solutions;

4. Data Empowerment:Build a surgical outcomes database to leverage real-world data for product iteration and precision marketing, achieving a dual-driven approach of technology and market.

The powerful collaboration between Shanghai Taimai and AccuPulse not only deepens their business cooperation but also marks a significant step forward in breaking new ground for high-end medical equipment produced in China. As domestically-made electrophysiology devices overcome "bottleneck" technologies, this precise battle for heart health is ushering in the dawn of a Chinese solution.